E. Kebebew, E. Reiff, Q. Duh, O. Clark, and A. Mcmillan, Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress?, World Journal of Surgery, vol.90, issue.5, p.8728, 2006.
DOI : 10.1007/s00268-005-0329-x

M. Fassnacht, S. Johanssen, M. Quinkler, P. Bucsky, H. Willenberg et al., Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma, Cancer, vol.356, issue.2, p.24350, 2009.
DOI : 10.1002/cncr.24030

G. Lughezzani, M. Sun, P. Perrotte, C. Jeldres, A. Alasker et al., The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation, Eur J Cancer Oxf Engl mars, vol.46, issue.4, p.7139, 1990.

M. Fassnacht, M. Kroiss, and B. Allolio, Update in Adrenocortical Carcinoma, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.12, p.455164, 2013.
DOI : 10.1210/jc.2013-3020

R. Libé, Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment, Frontiers in Cell and Developmental Biology, vol.3, p.45, 2015.
DOI : 10.3389/fcell.2015.00045

R. Mihai, Diagnosis, treatment and outcome of adrenocortical cancer, British Journal of Surgery, vol.6, issue.4, p.291306, 2015.
DOI : 10.1002/bjs.9743

R. Libé, I. Borget, C. Ronchi, B. Zaggia, M. Kroiss et al., Prognostic factors in stage III???IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study, Annals of Oncology, vol.26, issue.10, p.211925, 2015.
DOI : 10.1093/annonc/mdv329

L. Kirschner, The next generation of therapies for adrenocortical cancers, Trends in Endocrinology & Metabolism, vol.23, issue.7, p.34350, 2012.
DOI : 10.1016/j.tem.2012.04.001

T. Lehmann and T. Wrzesinski, The molecular basis of adrenocortical cancer, Cancer Genetics, vol.205, issue.4, p.1317, 2012.
DOI : 10.1016/j.cancergen.2012.02.009

B. Ragazzon, G. Assié, and J. Bertherat, Transcriptome analysis of adrenocortical cancers (ACC): from molecular classification to the identification of new treatments, Endocrine Related Cancer, vol.18, issue.2, p.1527, 2011.
DOI : 10.1530/ERC-10-0220

A. Stigliano, L. Cerquetti, C. Sampaoli, B. Bucci, and V. Toscano, Current and emerging therapeutic 36

G. Assié, A. Jouinot, and J. Bertherat, The 'omics' of adrenocortical tumours for personalized medicine, Nature Reviews Endocrinology, vol.20, issue.4, p.21528, 2014.
DOI : 10.1038/nrendo.2013.272

C. Gicquel, X. Bertagna, V. Gaston, J. Coste, A. Louvel et al., Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors, Cancer Res. 15 sept, vol.61, issue.18, p.67627, 2001.

T. Giordano, R. Kuick, T. Else, P. Gauger, M. Vinco et al., Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling, Clinical Cancer Research, vol.15, issue.2, p.66876, 2009.
DOI : 10.1158/1078-0432.CCR-08-1067

G. Assié, E. Letouzé, M. Fassnacht, A. Jouinot, W. Luscap et al., Integrated genomic characterization of adrenocortical carcinoma, Nature Genetics, vol.11, issue.6, p.60712, 2014.
DOI : 10.1038/ng.2953

D. Martino, M. , A. Ghuzlan, A. Aubert, S. Assié et al., Molecular Screening for a Personalized Treatment Approach in Advanced Adrenocortical Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.10, p.40808, 2013.
DOI : 10.1210/jc.2013-2165

L. Drougat, H. Omeiri, L. Lefèvre, and B. Ragazzon, Novel Insights into the Genetics and Pathophysiology of Adrenocortical Tumors, Frontiers in Endocrinology, vol.8, p.96, 2015.
DOI : 10.1371/journal.pone.0080725

URL : https://hal.archives-ouvertes.fr/inserm-01247515

B. Ragazzon, R. Libé, S. Gaujoux, G. Assié, A. Fratticci et al., Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers

J. Bezerra and A. Latronico, MicroRNA Era: The Importance for Diagnosis and Prognosis of Adrenocortical Tumors, BioMed Research International, vol.94, issue.3, p.381917, 2014.
DOI : 10.1158/0008-5472.CAN-10-2014

E. Duregon, I. Rapa, A. Votta, J. Giorcelli, F. Daffara et al., MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations, Human Pathology, vol.45, issue.8, p.155562, 2014.
DOI : 10.1016/j.humpath.2014.04.005

P. Igaz, I. Igaz, Z. Nagy, G. Nyír?, P. Szabó et al., MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy, Cellular and Molecular Life Sciences, vol.71, issue.5, p.41728, 2015.
DOI : 10.1007/s00018-014-1752-7

D. Özata, S. Caramuta, D. Velázquez-fernández, P. Akçakaya, H. Xie et al., The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma, Endocrine Related Cancer, vol.18, issue.6, p.64355, 2011.
DOI : 10.1530/ERC-11-0082

E. Patterson, A. Holloway, J. Weng, T. Fojo, and E. Kebebew, MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy, Cancer, vol.70, issue.8, p.16309, 2011.
DOI : 10.1002/cncr.25724

P. Soon, L. Tacon, A. Gill, C. Bambach, M. Sywak et al., miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer, Clinical Cancer Research, vol.15, issue.24, p.768492, 2009.
DOI : 10.1158/1078-0432.CCR-09-1587

C. Wang, Y. Sun, H. Wu, D. Zhao, and C. J. , Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers, Histopathology, vol.56, issue.4, p.56776, 2014.
DOI : 10.1111/his.12283

O. Chabre, R. Libé, G. Assie, O. Barreau, J. Bertherat et al., Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients, Endocrine Related Cancer, vol.20, issue.4, p.57994, 2013.
DOI : 10.1530/ERC-13-0051

D. Patel, M. Boufraqech, M. Jain, L. Zhang, M. He et al., MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors, Surgery, vol.154, issue.6, p.12248, 2013.
DOI : 10.1016/j.surg.2013.06.022

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874721

D. Szabó, M. Luconi, P. Szabó, M. Tóth, N. Szücs et al., Analysis of circulating microRNAs in adrenocortical tumors, Laboratory Investigation, vol.28, issue.3, p.3319, 2014.
DOI : 10.1016/S0002-9440(10)63846-1

P. Singh, P. Soon, J. Feige, O. Chabre, J. Zhao et al., Dysregulation of microRNAs in adrenocortical tumors, Molecular and Cellular Endocrinology, vol.351, issue.1, p.11828, 2012.
DOI : 10.1016/j.mce.2011.09.041

URL : https://hal.archives-ouvertes.fr/hal-00728034

C. Schoof, E. Botelho, S. Da, A. Izzotti, and L. Vasques, MicroRNAs in cancer treatment and prognosis, Am J Cancer Res, vol.2, issue.4, p.41433, 2012.

W. Ritchie and J. Rasko, Refining microRNA target predictions: Sorting the wheat from the chaff, Biochemical and Biophysical Research Communications, vol.445, issue.4, p.7804, 2014.
DOI : 10.1016/j.bbrc.2014.01.181

A. De-reyniès, G. Assié, D. Rickman, F. Tissier, L. Groussin et al., Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival, Journal of Clinical Oncology, vol.27, issue.7, p.110815, 2009.
DOI : 10.1200/JCO.2008.18.5678

U. Laemmli, Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4, Nature, vol.244, issue.5259, p.6805, 1970.
DOI : 10.1038/227680a0

H. Towbin, T. Staehelin, and J. Gordon, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications., Proceedings of the National Academy of Sciences, vol.76, issue.9, p.43504, 1979.
DOI : 10.1073/pnas.76.9.4350

M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak et al., Combination Chemotherapy in Advanced Adrenocortical Carcinoma, New England Journal of Medicine, vol.366, issue.23, p.218997, 2012.
DOI : 10.1056/NEJMoa1200966

M. Fassnacht, A. Berruti, E. Baudin, M. Demeure, J. Gilbert et al., Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study, The Lancet Oncology, vol.16, issue.4, p.42635, 2015.
DOI : 10.1016/S1470-2045(15)70081-1

L. Yao, J. Zhang, and X. Liu, : a Myc-repressed gene involved in cancer and cell stress, Acta Biochimica et Biophysica Sinica, vol.40, issue.7, p.62535, 2008.
DOI : 10.1111/j.1745-7270.2008.00434.x

V. Melotte, X. Qu, M. Ongenaert, W. Van-criekinge, A. De-bruïne et al., The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications, The FASEB Journal, vol.24, issue.11, p.415366, 2010.
DOI : 10.1096/fj.09-151464

J. Hwang, Y. Kim, H. Kang, L. Jaroszewski, A. Deacon et al., Crystal Structure of the Human N-Myc Downstream-regulated Gene 2 Protein Provides Insight into Its Role as a Tumor Suppressor, Journal of Biological Chemistry, vol.286, issue.14, p.1245060, 2011.
DOI : 10.1074/jbc.M110.170803

X. Hu, X. Liu, S. Lin, Y. Deng, N. Liu et al., NDRG2 expression and mutation in human liver and pancreatic cancers, World Journal of Gastroenterology, vol.10, issue.23, p.351821, 2004.
DOI : 10.3748/wjg.v10.i23.3518

M. Tepel, P. Roerig, M. Wolter, D. Gutmann, A. Perry et al., Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma, Int J Cancer J Int Cancer. 1 nov, vol.123, issue.9, p.20806, 2008.

H. Zhao, J. Zhang, J. Lu, X. He, C. Chen et al., Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer, BMC Cancer, vol.39, issue.2, p.303, 2008.
DOI : 10.1038/emm.2007.77

Y. Kim, S. Yoon, J. Kim, E. Song, H. Lee et al., NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma, Carcinogenesis. avr, vol.30, issue.4, p.598605, 2009.

A. Lorentzen, R. Lewinsky, J. Bornholdt, L. Vogel, and C. Mitchelmore, Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer, BMC Cancer, vol.124, issue.1, p.14, 2011.
DOI : 10.1002/ijc.23945

W. Cao, G. Yu, Q. Lu, and J. Zhang, Low expression of N-myc downstream-regulated gene 2 in oesophageal squamous cell carcinoma correlates with a poor prognosis, BMC Cancer, vol.385, issue.1, p.305, 2013.
DOI : 10.1016/j.bbrc.2009.05.038

S. Li, W. Wang, B. Li, C. B. Zhang, B. Wang et al., Expression of NDRG2 in human lung cancer and its correlation with prognosis, Medical Oncology, vol.10, issue.23, p.421, 2013.
DOI : 10.1007/s12032-012-0421-7

S. Oh, D. Kim, D. Kim, H. Chang, K. Sohn et al., NDRG2 correlated with favorable recurrence-free survival inhibits metastasis of mouse breast cancer cells via attenuation of active TGF-?? production, Carcinogenesis, vol.33, issue.10, p.18828, 2012.
DOI : 10.1093/carcin/bgs211

A. Yamamura, K. Miura, H. Karasawa, K. Morishita, K. Abe et al., Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer, Biochemical and Biophysical Research Communications, vol.441, issue.1
DOI : 10.1016/j.bbrc.2013.10.010

. Commun, 8 nov 2013, p.1027

D. Chu, Z. Zhang, Y. Zhou, Y. Li, S. Zhu et al., NDRG4, a novel candidate tumor suppressor, is a predictor of overall survival of colorectal cancer patients, Oncotarget, vol.6, issue.10, p.758496, 2015.
DOI : 10.18632/oncotarget.3170

R. Kotipatruni, X. Ren, D. Thotala, and J. Jaboin, NDRG4 is a novel oncogenic protein and p53 associated regulator of apoptosis in malignant meningioma cells, Oncotarget, vol.6, issue.19, p.17594604, 2015.
DOI : 10.18632/oncotarget.4009

X. Yang, L. An, and X. Li, NDRG3 and NDRG4, two novel tumor-related genes, Biomedicine & Pharmacotherapy, vol.67, issue.7, p.6814, 2013.
DOI : 10.1016/j.biopha.2013.04.009

N. Liu, L. Wang, X. Liu, Q. Yang, J. Zhang et al., Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines, Biochemical and Biophysical Research Communications, vol.358, issue.1, p.1649, 2007.
DOI : 10.1016/j.bbrc.2007.04.089

O. Barreau, G. Assié, H. Wilmot-roussel, B. Ragazzon, C. Baudry et al., Identification of a CpG Island Methylator Phenotype in Adrenocortical Carcinomas, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.1, p.17484, 2013.
DOI : 10.1210/jc.2012-2993

X. Chang, Z. Li, J. Ma, P. Deng, S. Zhang et al., DNA Methylation of NDRG2 in Gastric Cancer and Its Clinical Significance, Digestive Diseases and Sciences, vol.27, issue.3, p.71523, 2013.
DOI : 10.1007/s10620-012-2393-z

C. Fan, C. Wang, C. Tian, Y. Wang, L. Li et al., miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3, Oncol Rep. nov, vol.26, issue.5, p.12816, 2011.

L. Feng, Y. Xie, H. Zhang, and Y. Wu, Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650, Biochemical and Biophysical Research Communications, vol.406, issue.4, p.5348, 2011.
DOI : 10.1016/j.bbrc.2011.02.081

Q. Song, Y. Xu, C. Yang, Z. Chen, C. Jia et al., miR-483-5p Promotes Invasion and Metastasis of Lung Adenocarcinoma by Targeting RhoGDI1 and ALCAM, Cancer Research, vol.74, issue.11, p.303142, 2014.
DOI : 10.1158/0008-5472.CAN-13-2193

K. Krishnan, A. Steptoe, H. Martin, D. Pattabiraman, K. Nones et al., miR-139-5p is a regulator of metastatic pathways in breast cancer, RNA, vol.19, issue.12, p.176780, 2013.
DOI : 10.1261/rna.042143.113

D. Pereira, P. Rodrigues, P. Borralho, and C. Rodrigues, Delivering the promise of miRNA cancer therapeutics, Drug Discovery Today, vol.18, issue.5-6, pp.5-62829, 2013.
DOI : 10.1016/j.drudis.2012.10.002

N. Ghahhari and S. Babashah, Interplay between microRNAs and WNT/??-catenin signalling pathway regulates epithelial???mesenchymal transition in cancer, European Journal of Cancer, vol.51, issue.12, p.163849, 1990.
DOI : 10.1016/j.ejca.2015.04.021

M. Kim, J. Lim, Y. Yang, M. Lee, and J. Lim, N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial???mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling, Cancer Letters, vol.354, issue.1, p.3342, 2014.
DOI : 10.1016/j.canlet.2014.06.023

A. Golestan, Z. Mojtahedi, G. Ghalamfarsa, M. Hamidinia, and M. Takhshid, The Effects of NDRG2 Overexpression on Cell Proliferation and Invasiveness of SW48 Colorectal Cancer Cell Line, Iran J Med Sci. sept, vol.40, issue.5, p.4309, 2015.

D. Lee, S. Lee, J. Kim, J. Park, Y. Cho et al., Loss of NDRG2 promotes epithelialmesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression, J Hepatol. 17 août, 2015.

R. Li, C. Yu, F. Jiang, L. Gao, J. Li et al., Overexpression of N-Myc Downstream-Regulated Gene 2 (NDRG2) Regulates the Proliferation and Invasion of Bladder Cancer Cells In Vitro and In Vivo, PLoS ONE, vol.30, issue.10, p.76689, 2013.
DOI : 10.1371/journal.pone.0076689.t003